Bharat Parenterals Ltd
Bharat Parenterals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #9 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Standalone business is expected to achieve 12%-14% revenue growth in FY '26, with a 15%-17% EBITDA margin. - FY '27 standalone growth guided at 10%-12% annually over the next five years. - Innoxel Lifesciences targets Rs. Standalone business expected to deliver 12% to 14% revenue growth in FY '26 with EBITDA margins of 15% to 17%.
From Bharat Parenterals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Standalone business is expected to achieve 12%-14% revenue growth in FY '26, with a 15%-17% EBITDA margin.
- FY '27 standalone growth guided at 10%-12% annually over the next five years.
- Innoxel Lifesciences targets Rs. 110-135 crores revenue in FY '27, with EBITDA between Rs. 35-50 crores and poised to turn PAT positive.
- Commercial CMO supplies to start from Q1 FY '27, adding revenue streams beyond milestone receipts (Rs. 65-70 crores expected in FY '26).
- Varenyam Healthcare aims to cross Rs. 100 crore revenue in 18-24 months, with potential to reach Rs. 250-300 crores subsequently.
2 more points from Bharat Parenterals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Varenyam Bio total CapEx outlay is around Rs. 120 crores for the entire plant.
- Rs. 35 to 40 crores of investment has already been completed through internal accruals.
- Construction of general block is complete; oncology block construction has begun.
- Plant expected to be fully operational by FY '26 end.
- Regulatory approval phase to start early FY '27.
- Innoxel currently managing OPEX through milestone and licensing revenues; promoters step in for shortfalls.
2 more points from Bharat Parenterals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Bharat Parenterals has a significant institutional order of Rs. 210 crores received last year.
- The first tranche of this institutional order was completed in Q1 FY '26.
- The second and third tranches are expected to be completed in the second half (H2) of FY '26.
- The last tranche of this order is expected to be completed in Q1 of the next financial year.
- Order execution is on track and contributes to the anticipated 12-15% year-on-year revenue growth for the standalone business.
2 more points from Bharat Parenterals Ltd's call on order book
Create a free account to keep reading this call
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bharat Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bharat Parenterals Ltd Q2 FY26 results?
Standalone business is expected to achieve 12%-14% revenue growth in FY '26, with a 15%-17% EBITDA margin. - FY '27 standalone growth guided at 10%-12% annually over the next five years. - Innoxel Lifesciences targets Rs. Standalone business expected to deliver 12% to 14% revenue growth in FY '26 with EBITDA margins of 15% to 17%.
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,007 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Varenyam Bio total CapEx outlay is around Rs.
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.